Loading
Obesity / Low Energy Diet / CagriSema (Cagrilintide B + semaglutide I) · Phase 1 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 1 trial of the dual GLP-1/glucagon receptor agonist CagriSema combined with diet, measuring change in sleeping metabolic rate as the primary outcome over 20 weeks. No results are posted in this registry record; the study remains active but not recruiting.
Phase 1, Interventional, Randomized, Parallel, Open label, Treatment purpose. Obesity; age from 18 Years; to 65 Years. Intervention: CagriSema (Cagrilintide + Semaglutide) / CagriSema; Low Energy Diet (LED) / CagriSema. Compared with: Low-energy diet (calorie-reduced). n = 80. 2 sites: United States.
This is a planned Phase 1 trial of the dual GLP-1/glucagon receptor agonist CagriSema combined with diet, measuring change in sleeping metabolic rate as the primary outcome over 20 weeks. No results are posted in this registry record; the study remains active but not recruiting.
No results are reported in this registry record; efficacy and safety outcomes are unknown.
This Phase 1 study will generate preliminary safety and metabolic data on CagriSema in obese participants. Results are not yet available and should not be anticipated to guide clinical practice until efficacy is demonstrated in later-phase trials.
Phase 1 interventional study with no reported results; registry record describes planned enrollment and design only, insufficient to assess efficacy or safety outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This Phase 1 study will generate preliminary safety and metabolic data on CagriSema in obese participants. Results are not yet available and should not be anticipated to guide clinical practice until efficacy is demonstrated in later-phase trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07184086). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 80 participants (ESTIMATED). Conditions: Obesity. Interventions: DRUG: CagriSema (Cagrilintide B + semaglutide I); BEHAVIORAL: Low Energy Diet. Primary outcome measures: Change in sleeping metabolic rate (SMR) , Baseline (Week 0) to Week 20. Brief summary: In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.